2,3-bis(4-hydroxyphenyl)-propionitrile has been researched along with decitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darwish, HA; Diab, I; Helmy, MW; Motawi, TK; Noureldin, MH | 1 |
| Ghanem, H; Helmy, MW; Omran, GA; Salahuddin, A | 1 |
2 other study(ies) available for 2,3-bis(4-hydroxyphenyl)-propionitrile and decitabine
| Article | Year |
|---|---|
Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer.
Topics: Anticarcinogenic Agents; Azacitidine; beta Catenin; Caspase 3; Cell Proliferation; Cyclin D1; Decitabine; Disease Progression; Epigenesis, Genetic; Estrogen Receptor beta; Hormones; Humans; Hydroxamic Acids; Male; Methylation; Nitriles; Propionates; Prostate; Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
Epigenetic restoration and activation of ERĪ²: an inspiring approach for treatment of triple-negative breast cancer.
Topics: Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Decitabine; Epigenesis, Genetic; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Insulin-Like Growth Factor I; Nitriles; Propionates; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Vorinostat | 2022 |